Biogen Inc. (BIIB)

• Annual Data
• Quarterly Data

Biogen Inc., consolidated cash flow statement (quarterly data)

US$ in thousands

	3 months ended	Sep 30, 2019		Jun 30, 2019		Mar 31, 2019		Dec 31, 2018		Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014
	Net income
	Depreciation, amortization and impairments
	Acquired in-process research and development
	Share-based compensation
	Contingent consideration
	Loss on divestiture of Hillerød, Denmark manufacturing operations
	Deferred income taxes
	Unrealized (gain) loss on strategic investments
	Loss on equity method investment
	Other
	Accounts receivable
	Inventory
	Accrued expenses and other current liabilities
	Income tax assets and liabilities
	Other changes in operating assets and liabilities, net
	Changes in operating assets and liabilities, net
	Adjustments to reconcile net income to net cash flows from operating activities
	Net cash flows provided by operating activities
	Proceeds from sales and maturities of marketable securities
	Purchases of marketable securities
	Contingent consideration paid related to Fumapharm AG acquisition
	Acquisition of Nightstar Therapeutics plc, net of cash acquired
	Proceeds from divestiture of Hillerød, Denmark manufacturing operations
	Purchases of property, plant and equipment
	Acquired in-process research and development
	Acquisitions of intangible assets
	Purchase of Ionis Pharmaceuticals, Inc. stock
	Proceeds from sales of strategic investments
	Investment in Samsung Bioepis
	Acquisitions of business, net of cash acquired
	Other
	Net cash flows (used in) provided by investing activities
	Purchases of treasury stock
	Proceeds from (payments related to) issuance of stock for share-based compensation arrangements, net
	Proceeds from borrowings
	Repayment of borrowings
	Net distribution to noncontrolling interest
	Net cash contribution to Bioverativ Inc.
	Contingent consideration payments
	Excess tax benefit from share-based awards
	Other
	Net cash flows provided by (used in) financing activities
	Effect of exchange rate changes on cash and cash equivalents
	Net increase (decrease) in cash and cash equivalents

Based on: 10-Q (filing date: 2019-10-22), 10-Q (filing date: 2019-07-24), 10-Q (filing date: 2019-04-24), 10-K (filing date: 2019-02-06), 10-Q (filing date: 2018-10-23), 10-Q (filing date: 2018-07-24), 10-Q (filing date: 2018-04-24), 10-K (filing date: 2018-02-01), 10-Q (filing date: 2017-10-24), 10-Q (filing date: 2017-07-25), 10-Q (filing date: 2017-04-25), 10-K (filing date: 2017-02-02), 10-Q (filing date: 2016-10-26), 10-Q (filing date: 2016-07-21), 10-Q (filing date: 2016-04-21), 10-K (filing date: 2016-02-03), 10-Q (filing date: 2015-10-21), 10-Q (filing date: 2015-07-24), 10-Q (filing date: 2015-04-24), 10-K (filing date: 2015-02-04), 10-Q (filing date: 2014-10-22), 10-Q (filing date: 2014-07-23), 10-Q (filing date: 2014-04-23).